Want to join the conversation?
$LGND said the European Commission (EC) has approved Revolade (eltrombopag), a Novartis product, for the treatment of pediatric chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th